LONDON, Jan. 5, 2017 /PRNewswire/ -- The global clot
management market was valued at USD 1.26
billion in 2015 and is further expected to reach a value of
USD 1.88 billion by 2024, according
to a new report by Grand View Research, Inc. The market is expected
to grow with a CAGR of 4.6% owing to the key drivers such as
increasing prevalence of stroke, Pulmonary Embolism (PE), Deep Vein
Thrombosis (DVT), obesity, growing geriatric population,
technological advancements, and improvement in health insurance
coverage & availability of emergency medical services.
Globally, the number of people impacted by PE and DVT, which are
collectively known as Venous Thromboembolism (VTE), is much larger
than AIDS, cancer, and road traffic accidents combined
together.
The data published by the U.S. CDC indicates that stroke is amongst
the leading cause of disabilities and is the fifth leading cause of
deaths in the U.S. According to the estimates of CDC, PE and DVT
affect nearly 900,000 people in the U.S. Furthermore, the CDC
estimates also suggest the following:
Approximately 60,000 to 100,000 Americans die due to VTE and nearly
10% to 30% of the people are expected to die within 1 month of
their diagnosis
Nearly 33% of the people with VTE will have a recurrence within 10
years
In the U.S.,VTE accounts for over USD 10
billion in medical costs
The various risk factors that lead to VTE and stroke are classified
as high, medium, and other risks. The high risk factors include
hospitalization; spinal, hip, knee, & cancer surgeries; and
inactivity for long time due to various reasons, such as
postsurgery, sedentary lifestyle, etc. The moderate risk factors
include age above 60 years, family history of blood clots,
chemotherapy, and excessive use of estrogen-based medications. The
other risk factors include obesity, pregnancy, smoking, and alcohol
consumption.
The clot management devices market is also anticipated to grow due
to technological advancements and the launch of new-generation
thrombectomy devices, such as Penumbra's AC68 Reperfusion Catheter;
Trevo clot retrieval device manufactured by the Concentric Medical,
Inc.; and EmboTrap II Revascularization Device manufactured by
Neuravi.
Further Key Findings from the Study Suggest:
In 2015, percutaneous thrombectomy devices accounted for the
maximum share of over 35%. However, the neurovascular embolectomy
devices segment is expected to register the maximum CAGR of 6.2%
over the forecast period
Hospitals accounted for the maximum share of over 80%, as majority
of the stroke, DVT, and PE cases are treated in emergency and
critical care units. The demand for low-risk clot removal
procedures is anticipated to drive the diagnostic center
segment.
In 2015, North America held the
majority revenue share of over 60.5%. The growing awareness about
DVT/PE, access to advanced healthcare facilities, and presence of
robust reimbursement and regulatory framework are some of the key
reasons attributed to the high market share.
Asia Pacific is anticipated to be
the fastest growing region with a CAGR of 5.7% over the forecast
period.
Some of the key players in the clot management devices market
include Boston Scientific Corporation; Edwards Lifesciences;
Teleflex; Vascular Solutions, Inc.; Straub Medical; LeMaitre
Vascular; Medtronic; iVascular; and others
Download the full report:
https://www.reportbuyer.com/product/4523016/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/clot-management-devices-market-analysis-by-product-neurovascular-embolectomy-devices-embolectomy-balloon-catheters-percutaneous-thrombectomy-devices-catheter-directed-thrombolysis-devices-by-end-user-and-segment-forecasts-2-300386838.html
SOURCE ReportBuyer